Reuben Ben-David דר ראובן בן דוד

@RutgersCancer @montypal @saumyg @RWJBarnabas Well deserved! Congratulations

Congratulations to Dr. Saum Ghodoussipour @saumyg, Director of the Bladder and Urothelial Cancer Program at @RutgersCancer @RWJBarnabas, on being the first recipient of the flagship LG-UTUC Luminaries recognition! This honor is given to leaders who demonstrate expertise, and a commitment to advancing low‑grade upper tract urothelial cancer care. Congratulations Dr. Ghodoussipour! 👏 finance.yahoo.com/sectors/health…

@alirezaghoreifi @UrolOncol @DrChrisHoimes @hannahdzmd @michaelabern @AnkeetShahMD Great work, Alireza! In my personal experience, quite a substantial number of patients are on high-dose steroids due to AE related to this combination. Do you have any experience regarding tapering before surgery or increased complication rate, specifically among these patients?

Our @UrolOncol paper is live! Consolidative surgery after EVP: 1⃣Feasible for select advanced UCs 2⃣45% pCR; 59% downstaging 3⃣0 intraop complications; all margins- 4⃣Postop complications: 64% (27% HG) 5⃣Median FU 14 mo: 5 recurrences, 2 deaths 🔗authors.elsevier.com/a/1mtG53r93nkT…

📢Exciting news📢 ctDNA and NMIBC Bicenter collaboration. @JUrology-> Detectable pre-cystectomy ctDNA in patients with NMIBC was associated with: - Worse prognosis - Disease upstaging - pN+ disease 👁‍🗨doi.org/10.1097/JU.000… @SimaPorten @MehrazinMD @ahmederaky @DrJohnSfakianos

@ZivSavin @MantuGuptaMD @mario_sofer @Mendelson_Tomer @lrahmanimd @MountsinaiUro @UrologyTLVMC Great work!

Bladder stones ≠ mandatory BPH surgery: Personalizing males treatment. Take a look at our multicenter study. onlinelibrary.wiley.com/doi/10.1002/pr… @MantuGuptaMD @mario_sofer @Mendelson_Tomer @lrahmanimd @MountsinaiUro @UrologyTLVMC

I must admit that AI got it pretty right, ctDNA and robotic surgeries...Although, kitesurfing is still 👌🔥

@RicBertolo @DrSpratticus Radiation oncologists are trying to intelctualize on data while we see these patients weekly in the department. The question is, what treatment would you recommend to your father? The side effects and secondary malignancies associated with XRT are unpredictable and underreported.

@DrSpratticus This is an AI-generated visual abstract. It was not published in the journal. It did its job because it captured attention in a viral way (so viral that it seems to have touched a nerve in a certain crowd…). Read the article.

Good to know we can make up all data on a graph for this journal. X-axis intervals and just repeats 24 and 36 months. Y-axis shows curve going to basically 0% when it is supposed to be 42%. And we ask why the public doesn’t trust science and doctors 🤦🏻‍♂️ My 11 yo caught this…perhaps he should run that journal.

@jryckman3 @bernardorocco73 @RicBertolo @EurUrolOncol @minerviniandre @PaoloVerze @antopastl @lucacindolo @foxal72 @EAU_Uroonco @aleantonellibs1 @AgileGroupUro I wish you were right, radiation damage is cumulative over the years. I have at least one patient in any given week suffering from radiation related toxicity. Some of these patients are so frail that we try to do everything except cystectomy, no trial design can capture this.

@bernardorocco73 @RicBertolo @EurUrolOncol @minerviniandre @PaoloVerze @antopastl @lucacindolo @foxal72 @EAU_Uroonco @aleantonellibs1 @AgileGroupUro Salvage cystectomy for prostate RT? Even in bladder cancer, where the bladder receives full-dose RT, cystectomy for radiation toxicity is exceedingly rare. Suggesting otherwise reflects a poor grasp of modern radiotherapy practice.

Thank you @GUOncologyNow for highlighting our ctDNA study in RCC and for @MehrazinMD who is spearheading this investigation #SUO25 Preoperative, Postoperative Detectable ctDNA Predicts Worse Prognosis in Patients with Renal Masses Suspicious for RCC guoncologynow.com/post/preoperat…

@ahmederaky Congrats! You have put a lot of effort and thought into this paper, on its own it may transform the way we use imaging protocols after cystectomy in patients with undetectable ctDNA. Well deserved!

Honored to receive the SUO ‘Paper of the Year.’ I am sincerely grateful to my mentors at Mount Sinai for their constant guidance, high standards, and generosity with their time,this recognition reflects their mentorship as much as the science. #SUO2025

@urotoday @IcahnMountSinai @zklaassen_md @GACancerCenter @UroOnc Integration of ctDNA use in the management of NMIBC is showing promise. Patients with detectable ctDNA are not advised to undergo local bladder preserving therapies and some should be even considered for neoadjuvant therapy, even at this early stage.

Preoperative ctDNA predicts upstaging and recurrence in high-risk #NMIBC undergoing radical cystectomy. Presentation by @ReubenBenDavid1 @IcahnMountSinai. #SUO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4rEhD9G @UroOnc

❗️A study by @ReubenBenDavid1 and colleagues presented at #SUO25 has found that in patients with localized non-metastatic #RCC, the presence of detectable pre-nephrectomy ctDNA and anytime post-nephrectomy ctDNA had worse RFS: buff.ly/YoI14kl

Such a great opportunity to hear Dr. Yair Lotan on the changing paradigm of NMIBC treatment! We're thrilled to offer our patients with BCG-unresponsive disease even more options! Thanks to @IUOCisrael for organizing this great meeting! @UrologyTLVMC @RoyManoMD

@UroDocAsh @AmirHorowitz @shilpaonc @pjhensley11 @UrogerliMD @mouwlab @PGrivasMDPhD @AndreaNecchi @SimaPorten @spsutkaMD @urotoday @BladderCancerUS @WorldBladderCan Well deserved! Good luck

Welcome to the team, Amir! @AmirHorowitz @shilpaonc @pjhensley11 @UrogerliMD @mouwlab @PGrivasMDPhD @AndreaNecchi @SimaPorten @spsutkaMD @urotoday @BladderCancerUS @WorldBladderCan

📢📢 ctDNA and testicular cancer! doi.org/10.1111/bju.16… We are not there yet ‼️—> but with further investigation, I believe that ctDNA will ultimately demonstrate its merits in guiding decision-making and optimizing the management of testicular cancer. In our study, we examined the clinical utility of tumor-informed ctDNA in testicular cancer across several key scenarios, including clinical stage I disease, the peri-RPLND setting, and its potential role in refining and possibly relaxing surveillance protocols. @BJUIjournal @MehrazinMD @ahmederaky @DrJohnSfakianos

-> So excited about this!! 😲 One of the first reports on ctDNA performance in testicular cancer! Excellent multicenter collaboration to uncover 🗯 what the future of precision medicine holds for males who suffer from testicular cancer @JCOPO_ASCO

Pre-cystectomy ctDNA levels and metastatic recurrence in #BladderCancer patients. @ReubenBenDavid1 @IcahnMountSinai joins @zklaassen_md @GACancerCenter to discuss new research using Signatera to quantify ctDNA—not just detect it. 🔹 3 risk groups 🔹 Median progression: 5–12 mo 🔹 Upcoming #DECIDE trial #WatchNow on UroToday > bit.ly/4kVWIKK

ctDNA burden dynamics are yet another dimension of exploration in bladder cancer. ⬆️ High burden precystectomy ctDNA likely indicates a systemic disease, while ⬇️ low burden ctDNA can potentially be cured with multimodal approach, prospective trials are warranted. Thank you @urotoday for highlighting our abstract @DrJohnSfakianos.

@UCSFUrology @SimaPorten @Uro_Max @ben_breyer Congratulations!

Congratulations to Dr. Porten on her appointment as Chief of Urologic Oncology! A role that recognizes her exceptional clinical expertise, research leadership, and long-standing commitment to advancing care for patients with genitourinary cancer. urology.ucsf.edu/news/all/20250…